InChIKey	BLMPQMFVWMYDKT-NZTKNTHTSA-N
Compound Name	Carfilzomib
Canonical SMILES	CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1
Clinical Status	Data-mined Candidate
Targets (Human+Pathogen)	43
Pfam Stratification	Cross-Family
Avg pChEMBL	7.82
Source	ChEMBL;BindingDB

DrugBank ID	DB08889
Drug Name	Carfilzomib
CAS Number	868540-17-4
Groups	approved investigational
ATC Codes	L01XG02
Description	Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as ...

---

Categories: Amino Acids, Peptides, and Proteins Antineoplastic Agents Antineoplastic and Immunomodulating Agents Immunosuppressive Agents Myelosuppressive Agents Narrow Therapeutic Index Drugs P-glycoprotein inhibitors P-glycoprotein substrates P-glycoprotein substrates with a Narrow Therapeutic Index Peptides Proteasome Inhibitors

---

Cross-references: BindingDB: 50277889 ChEBI: 65347 CHEMBL451887 ChemSpider: 9731489 Drugs Product Database (DPD): 22678 D08880 PharmGKB: PA166165203 PubChem:11556711 PubChem:175427135 RxCUI: 1302966 Wikipedia: Carfilzomib ZINC: ZINC000049841054